Terms: = Sarcomas AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Prognosis
18 results:
1. Pathological characteristics and tumour immune microenvironment of lung malignancies with ret rearrangement.
Gao QY; Xiao FM; Lin XC; Chen YQ; Li YF; Lu C; Su JW; Tan QQ; Zhang CY; Yang J; Wu YL; Chen HJ; Yang JJ
Cancer Treat Res Commun; 2023; 35():100707. PubMed ID: 37121144
[TBL] [Abstract] [Full Text] [Related]
2. An integrative pan cancer analysis of ret aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract] [Full Text] [Related]
3. Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.
R Teixeira M; Oliveira J; Borralho P; O Fernandes MG; Almodovar T; Fernandes I; Macedo D; Ferreira A; Barroso A; Teixeira E; Machado JC
Acta Med Port; 2022 Sep; 35(9):677-690. PubMed ID: 35816050
[TBL] [Abstract] [Full Text] [Related]
4. Second Malignancies after Radiation Therapy: Update on Pathogenesis and Cross-sectional Imaging Findings.
Khanna L; Prasad SR; Yedururi S; Parameswaran AM; Marcal LP; Sandrasegaran K; Tirumani SH; Menias CO; Katabathina VS
Radiographics; 2021; 41(3):876-894. PubMed ID: 33891523
[TBL] [Abstract] [Full Text] [Related]
5. Functional impact of a germline ret mutation in alveolar rhabdomyosarcoma.
Berlow NE; Crawford KA; Bult CJ; Noakes C; Sloma I; Rudzinski ER; Keller C
Cold Spring Harb Mol Case Stud; 2021 Jun; 7(3):. PubMed ID: 33722797
[TBL] [Abstract] [Full Text] [Related]
6. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma.
Noguchi R; Yoshimatsu Y; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 Mar; 34(2):667-674. PubMed ID: 33146842
[TBL] [Abstract] [Full Text] [Related]
7. Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy.
Iñiguez-Ariza NM; Jasim S; Ryder MM; Chintakuntlawar AV; Morris JC; Hilger CR; Menefee ME; Smallridge RC; Karlin NJ; Alcaino C; Bible KC
J Clin Endocrinol Metab; 2020 Jul; 105(7):e2346-57. PubMed ID: 32421817
[TBL] [Abstract] [Full Text] [Related]
8. LncRNA MALAT1 Promotes Cancer Metastasis in Osteosarcoma via Activation of the PI3K-Akt Signaling Pathway.
Chen Y; Huang W; Sun W; Zheng B; Wang C; Luo Z; Wang J; Yan W
Cell Physiol Biochem; 2018; 51(3):1313-1326. PubMed ID: 30481748
[TBL] [Abstract] [Full Text] [Related]
9. Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study.
Schwegler C; Kaufmann D; Pfeiffer D; Aebi S; Diebold J; Gautschi O
Virchows Arch; 2018 Apr; 472(4):581-588. PubMed ID: 29198034
[TBL] [Abstract] [Full Text] [Related]
10. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract] [Full Text] [Related]
11. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract] [Full Text] [Related]
12. Outcomes of unplanned sarcoma excision: impact of residual disease.
Charoenlap C; Imanishi J; Tanaka T; Slavin J; Ngan SY; Chander S; Dowsey MM; Goyal C; Choong PF
Cancer Med; 2016 Jun; 5(6):980-8. PubMed ID: 26929181
[TBL] [Abstract] [Full Text] [Related]
13. New therapies for dedifferentiated papillary thyroid cancer.
Fallahi P; Mazzi V; Vita R; Ferrari SM; Materazzi G; Galleri D; Benvenga S; Miccoli P; Antonelli A
Int J Mol Sci; 2015 Mar; 16(3):6153-82. PubMed ID: 25789503
[TBL] [Abstract] [Full Text] [Related]
14. The PDCD4/miR-21 pathway in medullary thyroid carcinoma.
Pennelli G; Galuppini F; Barollo S; Cavedon E; Bertazza L; Fassan M; Guzzardo V; Pelizzo MR; Rugge M; Mian C
Hum Pathol; 2015 Jan; 46(1):50-7. PubMed ID: 25316501
[TBL] [Abstract] [Full Text] [Related]
15. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract] [Full Text] [Related]
16. [Advances in the diagnosis of ENT tumors in childhood].
Muñoz Borge F; González Alonso J; Galera Ruiz H; Delgado Moreno F; Galera Davidson H
An Pediatr (Barc); 2003 May; 58(5):456-63. PubMed ID: 12724079
[TBL] [Abstract] [Full Text] [Related]
17. Thyroid cancers. II. Medullary, anaplastic, lymphoma, sarcoma, squamous cell.
Austin JR; el-Naggar AK; Goepfert H
Otolaryngol Clin North Am; 1996 Aug; 29(4):611-27. PubMed ID: 8844733
[TBL] [Abstract] [Full Text] [Related]
18. Frequent loss of heterozygosity for markers on chromosome arm 10q in chondrosarcomas.
Raskind WH; Conrad EU; Matsushita M
Genes Chromosomes Cancer; 1996 Jun; 16(2):138-43. PubMed ID: 8818661
[TBL] [Abstract] [Full Text] [Related]
